Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors

Journal of Neurosurgery
Y YoshiiT Hoshino

Abstract

Twenty-five patients with tumors of the central nervous system received bromodeoxyuridine (BUdR), 200 mg/sq m, by intravenous infusion every 8 hours for 3 days before surgery. Excised tumor specimens were fixed in chilled 70% ethanol, embedded in paraffin, and cut into 6-micron sections. Each section was reacted with monoclonal antibodies against BUdR and stained with immunoperoxidase to identify nuclei that had incorporated BUdR. The growth fraction of each tumor was estimated by calculating the ratio of BUdR-positive nuclei to the total number of tumor cells in three to six microscopic fields in viable areas of the tumor. In seven cases, the tumor doubling time was measured from the serial computerized tomography scans and an attempt was made to estimate the cell cycle time. The growth fractions ranged from 9.1% to 46.5% in malignant gliomas, 2.0% to 6.7% in low-grade gliomas, 11.2% to 43.2% in metastatic brain tumors, 0.8% to 1.9% in pituitary adenomas, 3.9% to 4.6% in acoustic neurinomas, and 6.2% to 8.2% in meningiomas and cerebellar hemangioblastomas. The estimated cell cycle time was 5 to 12 days in most malignant gliomas and brain metastases; however, the actual cell cycle time should be substantially shorter because ce...Continue Reading

References

Sep 1, 1979·Cancer·T Hoshino, C B Wilson
Nov 1, 1985·Cytometry·M Vanderlaan, C B Thomas
Jul 1, 1972·Journal of Neurosurgery·T HoshinoD Fewer
Mar 1, 1971·The Japanese Journal of Surgery·S FujimotoK Okahara
Apr 1, 1967·The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine·M A BagshawT S Nelsen
Jan 1, 1984·International Journal of Radiation Oncology, Biology, Physics·T J KinsellaP Kornblith
Sep 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·F DolbeareJ W Gray

❮ Previous
Next ❯

Citations

Jul 12, 2002·The Journal of Gene Medicine·Miguel Sena-EstevesXandra O Breakefield
Oct 1, 1995·Journal of Neuro-oncology·Y YoshiiT Nose
Jan 1, 1994·Journal of Neuro-oncology·A FreeseM J O'Connor
Sep 1, 1988·Journal of Neuro-oncology·Y YoshiiK Sugiyama
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·H M SchipperE Wang
Sep 30, 1995·International Journal of Radiation Oncology, Biology, Physics·T L PhillipsI J Weigensberg
Aug 1, 1996·Nuclear Medicine and Biology·A BrunettiM Salvatore
May 31, 2001·International Journal of Radiation Oncology, Biology, Physics·S TribiusD Casper
Jan 20, 1996·Human Gene Therapy·A J VincentP M Hoogerbrugge
Aug 1, 1991·Journal of Neurosurgery·E C Alvord
Jul 1, 1993·Journal of Neurosurgery·Y TakamiyaR L Martuza
Jun 1, 1993·Surgical Neurology·P K KornblithM K Bradley
Mar 29, 2000·Journal of Theoretical Biology·A R KansalT S Deisboeck
Feb 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A M TsanaclisS Brem
May 1, 1989·Journal of Surgical Oncology·A YoshidaK Ito
Jan 25, 2005·Journal of Neuro-oncology·Sabine SteffensMiguel Sena-Esteves
Oct 1, 1995·Brain Pathology·C M KrammX O Breakefield

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.